These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1315470)

  • 1. Immunogenicity of experimental live attenuated Japanese encephalitis vaccine viruses and comparison with wild-type strains using monoclonal and polyclonal antibodies.
    Sil BK; Wills MR; Cao JX; Sharda R; Islam MA; Stagg DJ; Jennings AD; Gibson CA; Barrett AD
    Vaccine; 1992; 10(5):329-33. PubMed ID: 1315470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area.
    Wills MR; Sil BK; Cao JX; Yu YX; Barrett AD
    Vaccine; 1992; 10(12):861-72. PubMed ID: 1455912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses.
    Wills MR; Singh BK; Debnath NC; Barrett AD
    Vaccine; 1993; 11(7):761-6. PubMed ID: 8342323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
    Jia L; Wang Z; Yu Y
    Chin Med J (Engl); 2003 Jun; 116(6):941-3. PubMed ID: 12877812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
    Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
    Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2.
    Lee T; Komiya T; Watanabe K; Aizawa C; Hashimoto H
    Acta Virol; 1995 Jun; 39(3):161-4. PubMed ID: 8578998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children.
    Xin YY; Ming ZG; Peng GY; Jian A; Min LH
    Am J Trop Med Hyg; 1988 Aug; 39(2):214-7. PubMed ID: 2841880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.
    Yu Y
    Vaccine; 2010 May; 28(21):3635-41. PubMed ID: 20226891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.
    Gromowski GD; Firestone CY; Whitehead SS
    J Virol; 2015 Jun; 89(12):6328-37. PubMed ID: 25855730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies.
    Gupta AK; Lad VJ; Koshy AA
    Acta Virol; 2003; 47(3):141-5. PubMed ID: 14658841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the live-attenuated Japanese encephalitis vaccine SA14-14-2 strain with its pre-attenuated virulent parent SA14 strain: similarities and differences in vitro and in vivo.
    Yun SI; Song BH; Polejaeva IA; Davies CJ; White KL; Lee YM
    J Gen Virol; 2016 Oct; 97(10):2575-2591. PubMed ID: 27498826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B; Jia L; Xu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.